{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-086922","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.525014+00:00","generated_at":"2026-06-17T08:11:01.304180+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TScan CEO David Southwell steps down; Gavin MacBeath named acting CEO","bullets":["David Southwell resigned as CEO, President, and Board member effective March 27, 2023; no disagreement with company.","Gavin MacBeath, Ph.D., appointed acting CEO effective March 28, 2023; will continue as Chief Scientific and Operating Officer.","Southwell receives 18 months salary continuation and COBRA; severance conditioned on release and compliance with restrictive covenants.","Company reaffirms cash runway into Q2 2024 with $120M cash as of Dec 31, 2022; clinical programs on track.","First patient dosed with TSC-101 on March 9, 2023; plans to provide preliminary safety/biomarker data by mid-year 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-086922","json":"https://secwatch.observer/filing/0001193125-23-086922.json","markdown":"https://secwatch.observer/filing/0001193125-23-086922.md","text":"https://secwatch.observer/filing/0001193125-23-086922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523086922/0001193125-23-086922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523086922/d477438d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:11:01.304180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8916ff799b","claim":"David Southwell resigned as Chief Executive Officer and President at TScan Therapeutics, Inc..","evidence_excerpt":"On March 27, 2023, Mr. David Southwell stepped down from his roles as Chief Executive Officer and President of TScan Therapeutics, Inc. (the “Company”), and as a member of the Board of Directors of the Company (the “Board”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523086922/0001193125-23-086922-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"8e1106d300","claim":"Gavin MacBeath was appointed as acting Chief Executive Officer at TScan Therapeutics, Inc..","evidence_excerpt":"On March 28, 2023, the Board appointed Gavin MacBeath, Ph.D., as acting Chief Executive Officer of the Company, effective as of March 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523086922/0001193125-23-086922-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"acting Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}